“Lenacapavir is a product with real transformational potential that has the power to change the history of HIV,” Carolyn Amole of the Clinton Health Access Initiative (CHAI) told last week’s 13th ...

Two studies of children with HIV presented at the 13th International AIDS Society Conference on HIV Science (IAS 2025) in Kigali, Rwanda showed that even if they are on antiretroviral therapy (ART) ...

Artifical intelligence (AI) featured prominently at the 13th International AIDS Society Conference on HIV Science (IAS 2025) in Kigali, Rwanda last week. Experts expressed excitement – and some ...

Cuts in US funding for HIV programmes have already led to declines in testing and treatment starts in several countries, research presented last week at the 13th International AIDS Society ...

Garnering a standing ovation at IAS 2025, Sameer Sah, from Medical Aid for Palestinians, provided a devastating first-hand account of what’s been happening for nearly two years in Gazan healthcare ...

New data presented at the 13th International AIDS Society Conference on HIV Science (IAS 2025) yesterday show that two long-acting injectable PrEP options, lenacapavir and cabotegravir, are safe, well ...

Semaglutide and related weight-loss medications, known as GLP-1 agonists, may slow biological ageing, reduce inflammation, improve cognitive function and gut health, and reduce alcohol use in people ...

Letermovir, an antiviral drug for cytomegalovirus (CMV), was associated with reduced inflammation, improved CD4/CD8 T-cell ratios and better physical function for people with HIV on effective ...

Two more people appear to be free of HIV after stem cell transplants for cancer treatment, according to a pair of posters presented at the Conference on Retroviruses and Opportunistic Infections (CROI ...

A CRISPR-based gene-editing therapy called EBT-101 was safe and well tolerated but did not prevent viral rebound in three participants who stopped antiretroviral treatment in an early study, according ...

A symposium at the Conference on Retroviruses and Opportunistic Infections (CROI 2024) earlier this month included presentations advocating changes in practice on what might be called opposite ends of ...

The DoxyPEP trial enrolled more than 500 gay and bisexual men and transgender women in San Francisco and Seattle who were either living with HIV or taking PrEP. In 2022, Professor Annie Luetkemeyer of ...